Detalles de la búsqueda
1.
Pharmacokinetics of Intranasal Drugs, Still a Missed Opportunity?
Xenobiotica;
: 1-24, 2024 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38687903
2.
General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children.
Br J Clin Pharmacol;
88(12): 4985-4996, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36256514
3.
A Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of a Single Oral Dose of 5-HT1A Antagonist GSK958108 on Ejaculation Latency Time in Male Patients Suffering From Premature Ejaculation.
J Sex Med;
18(1): 63-71, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33223426
4.
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
Br J Clin Pharmacol;
87(1): 119-128, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32415684
5.
Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
Xenobiotica;
51(2): 177-193, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32902324
6.
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharm Res;
36(7): 93, 2019 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31044267
7.
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
Invest New Drugs;
36(3): 476-486, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177975
8.
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
J Pharmacokinet Pharmacodyn;
42(6): 611-26, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26209955
9.
Modeling of human tumor xenografts and dose rationale in oncology.
Drug Discov Today Technol;
10(3): e365-72, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24050133
10.
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis.
Clin Pharmacol Ther;
113(3): 692-703, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36524329
11.
Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction.
Clin Pharmacokinet;
61(9): 1297-1306, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35857278
12.
An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.
CPT Pharmacometrics Syst Pharmacol;
11(10): 1294-1304, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36047474
13.
Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer.
CPT Pharmacometrics Syst Pharmacol;
11(5): 569-580, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34755484
14.
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity.
Expert Opin Drug Discov;
16(11): 1365-1390, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181496
15.
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition.
Expert Opin Drug Metab Toxicol;
17(11): 1345-1352, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34720033
16.
A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
Clin Pharmacokinet;
60(12): 1605-1619, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34159557
17.
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis.
Clin Pharmacokinet;
60(9): 1239-1250, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33914285
18.
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
Clin Pharmacokinet;
60(9): 1227-1237, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33914286
19.
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
CPT Pharmacometrics Syst Pharmacol;
10(9): 1107-1118, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34273250
20.
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.
Clin Pharmacol Ther;
110(2): 297-310, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33270249